The Chinese government on 9 May issued proposals to amend the implementing rules of the existing national Drug Administration Law, the paramount legislation regulating the pharmaceutical industry in the country.
The changes are being perceived as providing new support and a renewed policy tailwind to Chinese drug makers, although the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?